Mitra Hariri, Abolghasem Jazayery, Mahmoud Jalali, Abbas Rahimi, Ebrahim Abdollahian,
Volume 9, Issue 3 (3-2012)
Abstract
Background and Aim: There is evidence showing that increased inflammatory mediators and reduced serum levels of polyunsaturated fatty acids may be present in patients with neurodevelopment and psychiatric disorders, e.g. attention-deficit/ hyperactivity disorder. (ADHD). The objective of this study was to determine the effects of dietary omega-3 fatty acid supplementation on hyperactivity, attention deficit, and serum inflammatory mediators in children with ADHD
Materials and Methods: This was an 8-week randomized double-blind clinical trial. The participants were 103 6 to12-year old children with ADHD receiving effective maintenance therapy, who were assigned randomly to receive either a daily omega-3 supplement (635 mg eicosapentaenoic acid and 195 mg docosahexaenoic acid (intervention group) or a placebo visually similar to the omega-3 capsules (placebo group). The serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were determined at baseline and at the end of the period. In addition, the abbreviated 10-item Conners parent rating scale (CPRS) was completed for each child before and after the intervention.
Results: The intervention brought about statistically significant reductions in the levels of CRP and IL-6 and a significant improvement in the CPRS score in the omega-3 group.
Conclusion: The findings indicate that dietary omega-3 fatty acid supplementation can have desirable effects on hyperactivity, attention deficit and inflammatory mediators in children with ADHD.
Mehrasa Mohammadsadeghi, Niaz Mohammadzadeh Honarvar, Mostafa Qorbani, Anahita Mansouri, Fariba Kouhdani,
Volume 16, Issue 2 (9-2018)
Abstract
Background and Aim: Lipoprotein disorders are an integral component of type-2 diabetes mellitus (T2DM). Therefore, early diagnosis and treatment of lipid disorders can be beneficial in prevention and treatment of many complications associated with T2DM.The aim of this study wasto determine the effect of docosahexaenoic acid (DHA) supplementation on the serum levels of apolipoproteins (Apos) A1, A2, B48 and C3 in patients withT2DM.
Materials and Methods: In this 8-week randomized, double-blind, placebo-controlled clinical trial, 44 T2DMpatients were randomly assigned to either an experimental group (n=22, receiving daily 2.4 g DHA) or a placebo group (n = 22, receiving paraffin). The serum levels of AposA1, A2, B48 and C3 were measured in all the patients at the beginning and at the end of the period.
Results: There was a statistically significant increase in the mean serum level of ApoA1 in the DHA group (p = 0.014). In addition, a significant difference was observed in the serum level of ApoC3 after intervention between the DHA and placebo group (p=0.031). There were no significant differences between the two groups as regards the mean changes in serum levels of ApoA1, ApoA2, ApoB48 and ApoC3.
Conclusions: Dietary supplementation with docosahexaenoic acidhasno effects on the serum levels of apolipoproteins in patients with type-2 diabetes.
